Matthew Wilson Schwartz - 29 Nov 2022 Form 4 Insider Report for THERALINK TECHNOLOGIES, INC.

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	THER	10% O.I.D. Senior Secured Convertible Debenture	Other	$120,999			$120,999	29 Nov 2022	Common Stock	40,332,963	$0.003000	Direct	F1, F2, F3, F4
transaction	THER	8% Convertible Promissory Note	Other	$105,216			$0	29 Nov 2022	Common Stock	21,008,403	$0.004800	Direct	F2
transaction	THER	Common Stock Purchase Warrant	Other	$0	+34,571,111	$0.000000	34,571,111	29 Nov 2022	Common Stock	34,571,111	$0.003000	Direct	F1, F2, F3, F5
transaction	THER	Common Stock Purchase Warrant	Other	$0	+4,201,681	$0.000000	4,201,681	29 Nov 2022	Common Stock	4,201,681	$0.003000	Direct	F6

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Id	Content
F1	Assumes a fixed conversion price of $0.003, but such conversion price is subject to adjustment as set forth in the debenture and warrant, respectively.
F2	The Reporting Person was issued a 10% Original Issue Discount ("O.I.D.") Senior Secured Convertible Debenture in the principal amount of $120,998.89 and 34,571,111 warrants in exchange for the 8% Convertible Promissory Note in the principal amount of $105,216 previously issued to the Reporting Person.
F3	The debenture and warrants described in footnote 2 are subject to mandatory conversion upon the occurrence of certain events, as outlined in the debentures and warrants, respectively. The original maturity date of the debentures was subsequently extended to February 29, 2024.
F4	Excludes shares issuable at the election of the Reporting Person upon conversion of accrued interest (both past and future) into shares of common stock.
F5	Expiration Date in the event a Qualified Offering is not consummated prior to the maturity date of the debentures the Warrants are issued in connection with.
F6	In connection with the note exchange describe in footnote 2, the Reporting Person entered into an amendment to its previously issued Common Stock Purchase Warrant amending the exercise price to $0.003 (and subject to adjustment in the event of certain fundamental transactions described in the amended warrant).